Starting July 1, seniors will get a rare break on weight-loss drugs. Medicare will launch a pilot program offering three GLP-1 medications for $50 a month, a fraction of the typical $450 cost that has kept millions of older Americans from affording the treatments.
The Centers for Medicare and Medicaid Services initiative, called Medicare GLP-1 Bridge, targets adults 65 and older with Medicare Part D coverage. Participants must meet strict criteria: a body mass index of 35 or higher, or one of two other qualifying conditions, and cannot have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease that might already be covered by existing plans.
For Kathryn, a 66-year-old retiree in Denver, the news arrives none too soon. She dropped from 220 pounds to 133 pounds after starting Zepbound two years ago, transforming her blood pressure and cholesterol. But the $450 monthly cost forced her to ration doses, preventing her from traveling in retirement as she had hoped. Thousands of seniors face the same financial squeeze.
About 5 million Americans over 65 currently take GLP-1 drugs, according to recent data, yet many stop using them because they cannot sustain the expense. The new program will cover Foundayo, Wegovy, and Zepbound through the end of 2027.
But the sudden flood of demand threatens to overwhelm the system. Doctors treating obesity worry the federal government may struggle to handle the volume. "It's a huge social and healthcare experiment to have this volume of people that are going to rely on the CMS website working, the pharmacy side working and the health system side all being able to process these prior authorizations in an efficient, effective way," said Dr. Annie Moore, an internist at CU Health in Denver. "This has never happened."
Dr. Christopher Weber, who treats obese patients exclusively in Milwaukee, expects clinic backlogs. "The clinics are going to be busy," he said. "Just keeping up with that demand and the administrative overhead is going to be a challenge." He notes he talks with at least five patients daily who would benefit from GLP-1 drugs but cannot afford them.
Moore estimates it could take three to four months before patients actually receive the $50 prescriptions. Even then, a $600 annual bill may remain out of reach for seniors on fixed incomes. "We still have a concern that some people will find $600 per year too expensive," she said.
The temporary nature of the program has sparked fresh anxiety. The Bridge initiative expires at the end of 2027, leaving patients and doctors unsure what happens next. Obesity, as one strategist noted, is not temporary. Dorothea Vafiadis, senior strategist for healthy aging at the National Council on Aging, captured the concern: "It's a temporary program; obesity is not a temporary problem." When people regain weight after stopping the drugs, she said, "people are scratching their heads, saying: 'What will I do then?'"
Another Denver resident, Carmin, has endured six major weight swings of 150 pounds each since childhood. She wanted to try GLP-1 therapy but skipped it to save for retirement. Now she is banking on the Bridge program to finally afford treatment. "The dream scenario for me is that by Christmas or next spring," she said, "I can get back into clothes I was wearing two years ago."
Author James Rodriguez: "This program could save millions of seniors from a drug that actually works, but Washington is gambling that the plumbing can handle the rush and that three years of relief won't leave people stranded when it ends."
Comments